[warning]In the last decade, a number of carbocyclic nucleoside analogs have been reported to posses interesting anti viral and anti cancer properties. We have communicated an article with the aforesaid title which would be available soon.[/warning]
The review article titled “Discovery and Development of Anti-HBV Agents and Their Resistance” is open access and can be downloaded by clicking the link on preview image of the article.
Image via Wikipedia Influenza viruses are a group of RNA viruses from Orthomyxoviridae family. These are 3 in number namely: Influenzavirus A, Influenzavirus B and Influenzavirus C. Each of these genus has only one species namely influenza A virus, influenza B virus and influenza C virus. Among the three, type A causes severe disease and … Read more
Carbocyclic Nucleosides is the name given to the class of molecules which are very similar to Nucleosides despite the fact that their furanose ring system in sugar counterpart is replace by a cyclopentyl ring. The first molecule, classified as Carbocyclic Nucleoside was Synthesized in a lab of Southern Research Institute in Birmingham, Albama. It was … Read more
The United States FDA‘s advisory committee has recommended that Truvada should be approved for HIV prophylaxis. Gilead Sciences Inc is the manufacturer of the drug to be used in combination therapy of AIDS. The drug is a RTI (Reverse Transcriptase Inhibitor), although it can not destroy the virus but stops their replication. Truvada consists of … Read more
Design & Development of Unnatural Nucleosides as Antiviral & Anti-Cancer Agents Ram C. Mishra College of Pharmacy, University of Georgia, GA 30602, USA Unnatural nucleosides are the variants (chemically modified analogs) of five natural nucleosides which constitute the structure of DNA and RNA. Since the first preparation and later, the isolation of unnatural … Read more
Recently (December 6th, 2013) Sofosbuvir was approved by US FDA for the treatment of Chronic Hepatitis C in combination with Ribavirin for dual therapy and with Ribavirin & Pegylated Interferon triple therapy for treatment-naive patients having HCV genotypes 1 and 4. The drug is being marketed as Sovaldi by Gilead.